Organogenesis Inc., a pioneer of regenerative medicine focusing on advanced wound care and surgical biologics, has entered into a revolving line of credit agreement with Silicon Valley Bank (SVB). This agreement provides $25 million of new capital to the company to be used for working capital and general corporate purposes.

"The people of Silicon Valley Bank are not only excellent bankers, but what sets them apart is they also understand business. We at Organogenesis are looking forward to building a strong, long-term relationship," said Tim Cunningham, Chief Financial Officer of Organogenesis Inc.

"Organogenesis is a pioneer in the field of regenerative medicine," said Kevin Longo, Director, Northeast Head of Medical Device and Digital Health, Silicon Valley Bank. "We're pleased to work with the Organogenesis team to provide the best financing, connections and global services they need to meet their corporate objectives."